Document is current
Any future updates will be listed below
-
Authors
Cox, Michelle J. https://orcid.org/0000-0002-2984-0834
Manriquez Roman, Claudia
Tapper, Erin E.
Siegler, Elizabeth L.
Chappell, Dale
Durrant, Cameron
Ahmed, Omar
Sinha, Sutapa
Mwangi, Raphael
Scott, Nancy S.
Hefazi, Mehrdad
Schick, Kendall J.
Horvei, Paulina
Ruff, Michael W.
Can, Ismail
Adada, Mohamad
Bezerra, Evandro
Kankeu Fonkoua, Lionel Aurelien
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
Sakemura, Reona
Kenderian, Saad S. https://orcid.org/0000-0003-2767-3830
- License Information
-
More Information
Article History
Received: 6 June 2021
Revised: 31 March 2022
Accepted: 4 April 2022
First Online: 19 April 2022
Competing interests
: SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis). MJC, RS, RMS and SSK are inventors on patents in the field of CAR immunotherapy that are licensed to Humanigen (through Mayo Clinic). MH and SSK are inventors on patents in the field of CAR immunotherapy that are licensed to Mettaforge (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis/Viracta, Leahlabs, and Lentigen. NEK receives research funding from Acerta Pharma, BMS, Pharmacyclics, MEI Pharma, and Sunesis. NEK has participated in Advisory Board meetings of Cytomx Therapy, Janssen, Juno Therapeutics, Astra Zeneca, and Oncotracker; and on DSMC for Agios and Cytomx Therapeutics. SAP receives research funding from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, BMS, AbbVie, and Ascentage Pharma. SAP has participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, GlaxoSmithKline, Verastem Oncology, and AbbVie (he was not personally compensated for his participation). CD, DC and OA are employees of Humanigen.
